Skip to main content
. Author manuscript; available in PMC: 2019 Sep 16.
Published in final edited form as: J Neuroimmune Pharmacol. 2016 Apr 16;11(2):369–377. doi: 10.1007/s11481-016-9670-0

Fig. 5.

Fig. 5

CCM lesion burden in a non-sensitized murine model after B cell depletion. Anti-BR3 antibody treatment of Pdcd10+/− mice significantly decreased the amount of mature stage 2 lesions, but did not affect the number of stage 1 pre-lesions, compared to untreated mice run contemporaneously. Horizontal lines indicate the mean (longer lines) and standard error of the mean (shorter lines)